The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (
Lutetium‐177‐PSMA‐617
metastatic castration‐resistant prostate cancer
pan‐immune inflammation value
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
29 Sep 2024
29 Sep 2024
Historique:
revised:
28
08
2024
received:
18
07
2024
accepted:
17
09
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Pan-immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 ( The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis. A total of 43 patients with mCRPC treated with ( This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with (
Sections du résumé
BACKGROUND
BACKGROUND
Pan-immune inflammation value (PIV) is a newly defined biomarker that includes whole cellular components that are indicators of systemic inflammation in complete blood count (CBC), easily accessible and has the potential to reflect both the body's immune response and systemic inflammation status. This study evaluated the pretreatment PIV for its prognostic impact on overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 (
METHODS
METHODS
The PIV was based on the earliest CBC obtained within 1 month before treatment initiation. Patients were categorized into low and high PIV groups based on the median pretreatment PIV, and the relationship between OS and PIV groups was assessed by multivariable analysis.
RESULTS
RESULTS
A total of 43 patients with mCRPC treated with (
CONCLUSION
CONCLUSIONS
This study showed that pretreatment PIV might be a prognostic factor in patients with mCRPC treated with (
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209‐249.
Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148‐1159.
Carles J, Castellano D, Climent MÁ, Maroto P, Medina R, Alcaraz A. Castration‐resistant metastatic prostate cancer: current status and treatment possibilities. Clin Transl Oncol. 2012;14(3):169‐176.
Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021;519:20‐29.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone‐sensitive prostate cancer. N Engl J Med. 2015;373(8):737‐746.
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer. N Engl J Med. 2017;377(4):352‐360.
Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first‐line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121‐131.
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration‐sensitive prostate cancer (PEACE‐1): a multicentre, open‐label, randomised, phase 3 study with a 2 × 2 factorial design. The Lancet. 2022;399(10336):1695‐1707.
Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate‐specific membrane antigen. Cancer Res. 1993;53(2):227‐230.
Afshar‐Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA‐617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697‐1705.
Hatano K, Nonomura N. Systemic therapies for metastatic castration‐resistant prostate cancer: an updated review. World J Men's Health. 2023;41(4):769‐784.
Sartor O, de Bono J, Chi KN, et al. Lutetium‐177‐PSMA‐617 for metastatic castration‐resistant prostate cancer. N Engl J Med. 2021;385(12):1091‐1103.
Filella X, Fernández‐Galán E, Fernández Bonifacio R, Foj L. Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers Med. 2018;11:83‐94.
Fucà G, Guarini V, Antoniotti C, et al. The pan‐immune‐inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled‐analysis of the valentino and TRIBE first‐line trials. Br J Cancer. 2020;123(3):403‐409.
Corti F, Lonardi S, Intini R, et al. The pan‐immune‐inflammation value in microsatellite instability‐high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Eur J Cancer. 2021;150:155‐167.
Susok L, Said S, Reinert D, et al. The pan‐immune‐inflammation value and systemic immune‐inflammation index in advanced melanoma patients under immunotherapy. J Cancer Res Clin Oncol. 2022;148(11):3103‐3108.
Shen L, Chen Z, Zhang Z, et al. Clinical efficacy of taxol plus platinum (TP) chemotherapy combined with delayed administration of PD‐1 inhibitors in patients with locally advanced, recurrent or metastatic esophageal squamous cell carcinoma: a retrospective study. DDDT. 2024;18:2761‐2773.
Lien MY, Hwang TZ, Wang CC, et al. A novel prognostic model using pan‐immune‐inflammation value and programmed death ligand 1 in patients with recurrent or metastatic head and neck squamous cell carcinoma receiving immune checkpoint inhibitors: a retrospective multicenter analysis. Target Oncol. 2024;19(1):71‐79.
Domański P, Jarosińska J, Kruczyk B, et al. Prognostic value of pan‐immune‐inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single‐center retrospective study. Współczesna Onkol. 2023;27(4):242‐248.
Zeng R, Liu F, Fang C, et al. PIV and PILE score at baseline predict clinical outcome of anti‐PD‐1/PD‐L1 inhibitor combined with chemotherapy in extensive‐stage small cell lung cancer patients. Front Immunol. 2021;12:724443.
Liu J, Lin P, Zhou B. Inflammation fuels tumor progress and metastasis. Curr Pharm Des. 2015;21(21):3032‐3040.
Yekedüz E, Tural D, Ertürk İ, et al. The relationship between pan‐immune‐inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. J Cancer Res Clin Oncol. 2022;148(12):3537‐3546.
Guven DC, Erul E, Yilmaz F, et al. The association between pan‐immune‐inflammation value and survival in head and neck squamous cell carcinoma. Eur Arch Otrhinolaryngol. 2023;280(5):2471‐2478.
Yazgan SC, Yekedüz E, Utkan G, Ürün Y. Prognostic role of pan‐immune‐inflammation value in patients with metastatic castration‐resistant prostate cancer treated with androgen receptor‐signaling inhibitors. Prostate. 2022;82(15):1456‐1461.
Van Wilpe S, Koornstra R, Den Brok M, et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology. 2020;9(1):1731942.
Yekedüz E, McKay RR, Gillessen S, Choueiri TK, Ürün Y. Visceral metastasis predicts response to new hormonal agents in metastatic castration‐sensitive prostate cancer. Oncologist. 2023;28(7):596‐603.
Pezaro CJ, Omlin A, Lorente D, et al. Visceral disease in castration‐resistant prostate cancer. Eur Urol. 2014;65(2):270‐273.
Fizazi K, Higano CS, Nelson JB, et al. Phase III, randomized, placebo‐controlled study of docetaxel in combination with zibotentan in patients with metastatic castration‐resistant prostate cancer. J Clin Oncol. 2013;31(14):1740‐1747.
Armstrong AJ, Garrett‐Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first‐line chemotherapy in men with castration‐resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203‐211.